Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$42.49 USD
-0.44 (-1.02%)
Updated May 9, 2024 04:00 PM ET
After-Market: $42.44 -0.05 (-0.12%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Earnings News For XENE
-
Xenon Pharmaceuticals: Q1 Earnings Snapshot
-
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
-
Xenon Pharmaceuticals: Q4 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals: Q3 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals: Q2 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates
-
Xenon Pharmaceuticals: Q1 Earnings Snapshot
-
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?
-
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
-
Xenon Pharmaceuticals: Q4 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals: Q3 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals: Q2 Earnings Snapshot
-
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates
-
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates